Table 1.

Patient Population Throughout Study Participation

Characteristic	Value
Sex, No. (%)  Male	18 (60)
Female	12 (40)
Age, mean (95% CI), y	15.1 (13.5–17.8)
Height, mean (95% CI), cm	170 (165–175)
Weight, mean (95% CI), kg  At enrollment	97 (82–108)
End of placebo phase	98 (84–106)
End of allopurinol phase	96 (83–108)
BMI at enrollment, mean (95% CI)	33 (28–36)
BMI percentile at enrollment, mean (95% CI)	94.3 (91.1–99.5)
Race/ethnicity, No. (%)  White	14 (47)
Black	9 (30)
Hispanic	7 (23)
Serum uric acid, mean (95% CI), mg/dL  At enrollment	6.9 (6.5–7.4)
Beginning of placebo phase	6.2 (5.5–6.9)
End of placebo phase	6.4 (5.8–7.0)
Beginning of allopurinol phase	7.0 (6.5–7.5)
End of allopurinol phase	4.2 (3.7–4.6)
Casual systolic BP, mean (95% CI), mm Hg  At enrollment	139 (137–141)
Beginning of placebo phase	139 (135–141)
End of placebo phase	137 (135–140)
Beginning of allopurinol phase	137 (134–142)
End of allopurinol phase	132 (129–134)
Casual diastolic BP, mean (95% CI), mm Hg  At enrollment	83 (80–85)
Beginning of placebo phase	82 (79–85)
End of placebo phase	81 (78–83)
Beginning of allopurinol phase	83 (80–86)
End of allopurinol phase	78 (74–80)
24-Hour ambulatory systolic BP, mean (95% CI), mm Hg  At enrollment	127 (124–130)
End of placebo phase	128 (124–132)
End of allopurinol phase	120 (117–123)
24-Hour ambulatory diastolic BP, mean (95% CI), mm Hg  At enrollment	74 (69–83)
End of placebo phase	74 (70–76)
End of allopurinol phase	68 (65–70)

Abbreviations: BMI, body mass index (measured as weight in kilograms divided by height in meters squared); BP, blood pressure; CI, confidence interval.

SI conversion factor: To convert uric acid to μmol/L, multiply values by 59.485.